Search for dissertations about: "Factor VIII"
Showing result 11 - 15 of 48 swedish dissertations containing the words Factor VIII.
-
11. Pharmacometric Approaches to Improve Dose Individualization Methods in Hemophilia A
Abstract : Hemophilia A is a bleeding disorder caused by the lack of functional coagulation factor VIII (FVIII). The overall aim of this thesis was to improve dose individualization of FVIII replacement therapy in hemophilia A using pharmacometric approaches. READ MORE
-
12. Factor V Leiden mutation and pregnancy. Haemostasis during pregnancy in non-carriers and carriers of factor V Leiden mutation, with special emphasis on placenta-mediated and venous thromboembolic complications and on blood coagulation and fibrinolysis markers for prediction of complications
Abstract : Factor V Leiden (FVL) mutation elevates the risk of venous thromboembolism (VTE) in general. During pregnancy, the haemostatic balance is changed in the direction of hypercoagulability, resulting in an increased incidence of VTE. 42 women were followed longitudinally during pregnancy and the puerperium. READ MORE
-
13. Haemophilia B - Diagnostic Insights, Genetic Aspects and Clinical Outcomes
Abstract : Haemophilia B (HB) is a rare inherited bleeding disorder caused by the deficiency of coagulation factor IX (FIX). The major clinical issues are bleedings, often targeting the joints, and the development of neutralising antibodies, i.e. inhibitors, to the FIX replacement therapy. READ MORE
-
14. The N-terminal EGF Module of Coagulation factor IX. Studies of Calcium Binding and Module Interactions
Abstract : Coagulation factor IX (FIX) is a vitamin K-dependent serine protease zymogen that circulates in plasma. Defects in FIX cause the bleeding disorder hemophilia B. FIX contains a Gla module, two Epidermal Growth Factor (EGF) -like modules and a serine protease region. READ MORE
-
15. Rational and Combinatorial Engineering of Affinity Proteins Towards Therapeutical Applications
Abstract : Protein engineering has had an immense impact on the development of biological drugs, including replacement therapies with engineered versions of insulin or factor VIII to treat diabetes or bleeding disorders, and monoclonal antibodies to treat cancer and various other malignancies. Now, with the next generation of treatment modalities coming up, including monoclonal reagents based on alternative scaffolds, gene and cell therapies, the importance of protein engineering to tailor-make these treatments is likely to increase further. READ MORE